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Abstract
Background: Neovascular age-related macular degeneration is the leading cause of irreversible blindness in people
50 years of age or older in the developed world. As in other chronic diseases, several effective treatments are
available, but in clinical daily practice there is an evidence performance gap. The Chronic Care Model represents an
evidence-based framework for the care of chronically ill patients and aims at closing that gap. However, no data
are available regarding patients with neovascular age-related macular degeneration.
Methods/Design: CHARMED is a multicenter randomized controlled trial. The study challenges the hypothesis that
the implementation of core elements of the Chronic Care Model (patient empowerment, delivering evidence
based information, clinical information system, reminder system with structured follow up and frequent
monitoring) via a specially trained Chronic Care Coach in Swiss centres for neovascular age-related macular
degeneration results in better visual acuity (primary outcome) and an increased disease specific quality of life
(secondary outcome) in patients with neovascular age-related macular degeneration. According to the power
calculation, a total sample size of 352 patients is needed (drop out rate of 25%). 14 specialised medical doctors
from leading ophtalmologic centres in Switzerland will include 25 patients. In each centre, a Chronic Care Coach
will provide disease specific care according to the Chronic Care Model for intervention group. Patients from the
control group will be treated as usual. Baseline measurements will be taken in month III - XII, starting in March
2011. Follow-up data will be collected after 6 months and 1 year.
Discussion: Multiple studies have shown that implementing Chronic Care Model elements improve clinical
outcomes as well as process parameters in different chronic diseases as osteoarthritis, depression or e.g. the
cardiovascular risk profile of diabetes patients. This study will be the first to assess this approach in neovascular
age-related macular degeneration. If our hypothesis will be confirmed, the implementation of this approach in
routine care for patients with with neovascular age-related macular degeneration should be considered.
Trial Registration: Current controlled trials ISRCTN32507927.
Background
According to estimates of the World Health Organiza-
tion, chronic diseases will represent the major challenge
for health care systems in the developed world [1]. Due
to demographic changes, the prevalence of chronic dis-
eases will rise up to a prevalence of 60%. Faced with
this tremendous development, evidence based
approaches for the care for chronically ills are the
purpose of many research projects. Based on the aggre-
gated evidence, Wagner and colleagues developed the
C h r o n i cC a r eM o d e l( C C M )w i t h6k e yd i m e n s i o n so f
care (organization of health care, clinical information
systems, delivery system design, decision support, self-
management support, community resources) as a con-
ceptual framework for the care for chronically ills [2-5].
The aim of the Chronic Care Coach (CCC) is to inte-
grate all evidence-based concepts or approaches into
this conceptual framework. One of the major problems
addressed by the CCM is the fact that current care of
chronically ills is often reactive and triggered by actual
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planned [6]. Core elements of the CCM are patient
empowerment, providing evidence based information for
patients and physicians, as well as frequent monitoring
and structured follow up. Several studies have shown
that nurse practitioners or specially trained practice can
carry out most of these tasks. Especially telephone based
f o l l o wu pa n dc a s em a n a g e m e n th a sb e e np r o v e nt ob e
an effective and efficient approach to ensure appropriate
monitoring, especially regarding chronic diseases. Sev-
eral studies reported significant improvements in pro-
cess parameters as well as in clinical outcomes in
common diseases as e.g. diabetes, osteoarthritis and
even depression care [7-9].
Neovascular age-related macular degeneration (wet
AMD) is a typical chronic disease and the leading cause
of irreversible blindness in people 50 years of age or
older in the developed world [10,11]. As in other
chronic diseases, several effective treatments are avail-
able, but clinical experience has shown that these treat-
ments are not as frequently provided as clinical evidence
suggests [12]. Daily practice is characterized by an evi-
dence performance gap. Wet AMD as well as other
mostly age-related causes of ocular morbidity are on the
rise in all industrialized countries and associated with a
tremendous loss of quality of life [13,14]. Since wet
AMD is a chronic disease, it can be hypothesized that
treatment approaches focussing on a structured moni-
toring and follow-up may also result in improved out-
comes in wet AMD.
This study challenges the hypothesis that the imple-
mentation of core elements of the CCM (patient
empowerment, delivering evidence based information,
clinical information system, reminder system with struc-
tured follow up and frequent monitoring) results in bet-
ter visual acuity in patients suffering from wet AMD, an
increased disease specific quality of life (outcomes),
mediated by a better treatment adherence.
Methods
Trial design
A multicenter randomized controlled trial with the
patient as the unit of randomization. The flow chart of
the study is described in Figure 1.
Participants
All eligible patients with wet AMD who are treated in
selected centres in Switzerland will be addressed conse-
cutively by the physicians and informed about the study
with written material.
Inclusion criteria for patients
■ Male or female patients with wet AMD
■ Eligible for a therapy with anti-angiogenic drug
■ Visual acuity ≥ 0.05 (assessed by Early Treatment
Diabetic Retinopathy Study [ETDRS] charts)
■ Age > 50 years
Written informed consent given before any study
related procedure is performed
Exclusion criteria for patients
■ Serious general or psychological illness (advanced
malignant tumours, serious depressive episodes, evi-
dence of dementia)
■ Insufficient language skills (informed consent,
patient information and questionnaires will be provided
in German and French)
■ Patients with any invasive medical treatment for wet
AMD in the past
Intervention
The aim of the intervention is to implement established,
evidence based core elements of the CCM in the care
for patients with wet AMD. Wet AMD is as diabetes,
asthma, hypertension etc. a chronic disease with evi-
dence (according to guidelines) that frequent monitor-
ing/follow ups and treatments as needed increase visual
acuity and quality of life. In daily practice frequent fol-
low ups and monitoring are often lacking. Therefore, in
each centre a specially trained chronic care coach (in
half-day workshops) will monitor the treatment, includ-
ing telephone reminders, patient information and direct
self-management support in the centre. Evidence based
information on the treatment and the need for a
monthly follow up will be provided to patients. Patient
empowerment according to established programs will be
provided during meetings with professionals, peer group
meetings and by peer contact persons.
In detail the key elements of the CCM will be
addressed as follows:
Organization of health care delivery system
The specially trained CCCs will monitor and organize
the treatment and structure and plan the contacts
between patients and physicians. They will call the
patient monthly, if necessary more frequently upon
request of the patient. During the calls, the self-mea-
sured data of the visual acuity with the Amsler-test and
the Health Management Tool (HMT), assessed by
iPhone, will be asked. The HMT measures retinal visual
function via a contrast contour test. To perform these
phone calls and assessments, the CCCs will be trained
in one day sessions. Since the CCCs are also involved in
the treatment of patients in the control group, a “leak-
age” of information about the CCM cannot completely
be avoided. But the main elements of the intervention
(iPhone, phone calls from the CCC, peer group meeting)
are definitely only accessible to patients within the study
group.
Frei et al. Trials 2011, 12:221
http://www.trialsjournal.com/content/12/1/221
Page 2 of 8Self-management support
Self management is an important issue in chronic dis-
eases. Several interventions will be provided to patients
in this study to increase their self management:
1. Initially, patients will be individually taught by the
CCC. The CCC will also be the contact person at
the study centre in case of further queries. Patients
will be instructed to measure the visual acuity of
both eyes weekly (with the Amsler-test and the
HMT). All patients will be instructed initially by the
CCC on how to handle these tools. To assess the
efficacy of the HMT, all contacts initiated from the
patient due to the self assessment of visual acuity by
means of the HMT will be assessed separately.
2. Patients will receive an action plan, which will tell
them how to deal with the disease, to estimate the
severity of symptoms for subsequent needed actions
and how to react if they recognize any changes in
the visual acuity. Furthermore, the action plan
Figure 1 Flow chart.
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tact information of the CCC.
3. Peer group meetings are known to be effective inter-
ventions; therefore, peer group meetings with experi-
enced patients suffering from wet AMD will take place
at least twice in collaboration with Retina Suisse, the
Swiss patient organisation for retinal diseases. Peer
contacts (patients with wet AMD who are available for
queries) will be able to support patients additionally.
Decision support
Evidence-based information, based on published guide-
lines and patient information leaflets will be provided
with detailed information about what to do ("Don’t
worry” leaflet and “Call immediately” leaflets), including
a checklist for the antibiotic eye drops and all important
contact addresses. Also a timetable to conduct the HMT
and the Amsler self-tests will be provided to the patients.
Delivery system design and Clinical information systems
Appropriate IT and data bases ease a frequent and
structured follow-up. The positive effect of reminder
systems on the quality of care for chronically ills has
been well documented. Therefore, a computer based
reminder system with structured follow up and frequent
monitoring will be implemented in all centres to orga-
nise the monthly visits for injections and the monthly
scheduled phone calls but used only for the monitoring
of the patients in the intervention group. The first 3
dates will be fixed with this system automatically.
Outcomes
The outcome parameters and instruments which are
used in the study are summarized in tables 1, 2 and 3.
Primary outcome
The primary outcome is the visual acuity. The measure-
ments will be taken under standardised conditions in
the centres in a sitting position at an initial test distance
of 4 meters using ETDRS charts [15,16]. To assure stan-
dardized measurements, each study centre will be visited
and teached accordingly by our study team. Each study
centre will be controlled on outreach visits at minimum
once within the study period. Besides the name of the
equipment used in each study centre will be listed in
our study data.
The chart has five letters of the same size per row and
14 rows it total, and the letters of the following rows
become gradually smaller (with a difference of 0.1 log-
MAR). The outcome value will be the number of letters
correctly read by the patient. The power calculation is
based on the ETDRS.
Secondary outcomes
Disease specific quality of life
Disease specific quality of life will be assessed by a well
established patient-reported outcome measure, the
National Eye Institute Visual Function Questionnare-25,
interviewer version (NEI VFQ-25) [17,18]. The NEI
VFQ-25 was developed based on qualitative research
with patients to measure the range of vision-related
functioning. It contains 12 subscales: general vision,
near vision, distance vision, driving, peripheral vision,
colour vision, ocular pain, general health, vision specific
role difficulties, dependency, social function, and metal
health. Subscale scores are calculated by summing the
appropriate items and transforming the raw scores into
a 0 to 100 scale (higher scores indicate better function-
ing or well-being), the total score is an average of 11
subscale scores, excluding the single item general health
subscale. The NEI VFQ-25 has shown to be a valid and
easy to use instrument, showing a high correlation with
the visual acuity [19-21]. The German and French trans-
lation of the NEI VFQ-25 has been validated [22,23].
Physiological outcome
The central retinal thickness will be routinely assessed
by the optical coherence tomography (OCT).
Health services utilisation
CCM aims at decreasing inappropriate use of the health
care system by a proactive management. To assess if
our intervention can fulfil this goal, we will assess
patients’ health service utilisation during the study per-
iod and the year before the study started. Patients will
be asked to self-report all contacts to physicians in pri-
vate practice, hospitals and emergency rooms. We will
distinguish as far as possible between wet AMD asso-
ciated consultations and consultations associated with
other reasons/diseases.
The HMT enables patients to self perform a measure-
ment of visual acuity. To assess whether this application
increases the adherence, appointments triggered by the
HMT will be assessed separately. The CCC will
Table 1 Assessment by physicians/clinical visits in the
centres = > assessed by questionnaire
Baseline After 6
months
1)
After 12
months
Visual acuity: ETDRS x x x
Central retinal thickness:
OCT
xx x
Comorbidities x x
Family anamnesis of wet
AMD
xx
Smoking x x
Medication x x
ACIC
2) xx
Outcome-parameters and time of assessment of the study
1) Additional questionnaire 6 month only with ETDRS and OCT assessment
2) Additional questionnaire
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the initiator of the encounter (patient/physician/chronic
care coach/other).
Accordance to the CCM
Patients’ perspective Patients’ assessment of the pro-
vided care will be assessed with the Patient Assessment
of Chronic Illness Care (PACIC) which has been devel-
oped to assess congruency of provided health care to
the CCM [24]. It is organized according to the key ele-
ments of the CCM and assesses the behavior of profes-
sionals and practice teams from a patient’sp e r s p e c t i v e .
The PACIC contains 20 items assessing 5 scale con-
structs: patient activation (assesses to what extent the
patient was motivated and supported by the physician to
initiate changes), delivery system design/decision sup-
port (assesses if the patient was supported e.g. by book-
lets and how satisfied he was with the organization of
his care), goal setting/tailoring (assesses to what extent
general instructions and suggestions were adapted to his
personal situation), problem solving/contextual (assesses
how the physician dealt with problems which interfered
with achieving predefined goals), follow-up/coordination
(addresses how frequently and consequently the whole
process was followed-up). Recently, a German version of
the PACIC has been validated in a sample of osteoar-
thritis patients [25]. The PACIC was also validated in a
sample of diabetes patients [24] and its psychometric
properties have been shown good in primary care
patients with major depression [26].
Provider perspective To assess accordance to the CCM
of the health care provider’s perspective, the Assessment
of Chronic Illness Care (ACIC) [27] will be used. The
ACIC is aimed at organizational teams to help identify-
ing areas for improvement in their care for chronic ill-
nesses and to evaluate the level and nature of
improvements made in their system. It consists of 28
items covering the six areas of the CCM: Organization
of the healthcare delivery system (6 items), community
linkages (3 items), self-management support (4 items),
decision support (4 items), delivery system design (6
items) and clinical information systems (5 items).
Responses fall within four descriptive levels (D, C, B, A)
of implementation ranging from D “little or none” to A,
a “fully implemented” intervention. Within each of the
four levels, respondents are asked to choose one of
three ratings of the degree to which that description
applies. The result is a 0-11 scale, with categories
defined as follows: 0-2 (little or no support for chronic
illness care), 3-5 (basic or intermediate support for
chronic illness care), 6-8 (advanced support) and 9-11
(optimal, or comprehensive, integrated care for chronic
illness). Subscale scores for the six areas are derived by
summing the response. Bonomi et al. showed all six
ACIC subscale scores to be responsive to health care
quality-improvement efforts [27]. A translated and cul-
turally adapted version into German has just been vali-
dated by the authors [28].
Confounder control
Depression is highly prevalent among patients with
chronic diseases and has been identified as important
predictor for quality of life as well as clinical outcomes. It
can also be an important confounder for the assessment
of the success of interventions, aiming at improving qual-
ity of life. Therefore, we will assess depression by means
of the Prime MD Patient Health Questionnaire (PHQ-9)
[29]. The PHQ-9 is an established instrument to assess
depression, especially in a primary care setting [7,30].
Furthermore, we assess the diabetes diagnosis as a
potential confounder because of the diabetes patients’
risk for diabetic retinopathy.
Table 2 Assessment by chronic care coach by telephone monitoring
Baseline M
2
M
3
M
4
M
5
After 6
months
M
7
M
8
M
9
M
10
M
11
After 12
months
NEI VFQ-25
1) xx x
Self-measured visual acuity test: Amsler-test (weekly, at home) x x x x x x x x x x x x
Retinal visual function assessments by iPhone (contrast contour
test, weekly, at home)
x x x x xxx x x x x x
Outcome-parameters and time of assessment of the study
1) Interviewer version (assessed if possible in direct patient contact, if not by telephone)
Table 3 Assessments by patient questionnaire
Baseline After 6
months
After 12
months
Health services
utilisation
xx
PHQ-9 x x
PACIC x x
Sociodemographics x x
Outcome-parameters and time of assessment of the study
Abbreviations for the tables:
EDTRS: Early Treatment Diabetic Retinopathy Study
OCT: Optical Coherence Tomography
Wet AMD: Neovascular age-related macular degeneration
ACIC: Assessment of Chronic Illness Care
NEI VFQ-25: National Eye Institute Visual Function Questionnaire-25
PHQ-9: Prime MD Patient Health Questionnaire (Depression Scale)
PACIC: Patient Assessment of Chronic Illness Care
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The CCCs will fill in the participants’ names into a list in
order of their inclusion and allocate a code to each patient.
This code is also marked on all questionnaires and patient
data which will be sent to the Institute of General Practice
and Health Services Research at the University of Zurich.
Therefore, the university only receives the patients’ codes
and has no access to their names.
Data regarding visual acuity assessed by the standar-
dised ETDRS test and the clinical outcome OCT will be
r o u t i n e l ya s s e s s e db yt h ep h y s i c i a n s .T h eN E IV F Q - 2 5
will be provided to the patients by the trained CCC
(assessed face-to-face, if this is not possible it will be
assessed by telephone).
Patients will receive a questionnaire, containing socio-
demographic variables, data about health service utiliza-
tion, the PACIC [24] and the PHQ-9 [29], and a
stamped envelope with the postal address of the univer-
sity. The patients are asked to return this questionnaire
in the envelope to the university. Health care providers
will not get knowledge about the collected data to avoid
any influence on the adherence, especially in the control
group (via increased awareness by decreasing scores).
A second questionnaire is filled out by the physicians
and/or the CCC for each participant regarding the
actual ETDRS test values, central retinal thickness (via
OCT), comorbidities, smoking status as a known risk
factor [31,32] and medication. This questionnaire is
marked as well with the patient’s code and will be
returned to the university in a stamped envelope. Addi-
tionally, the physicians fill out the ACIC.
Data regarding visual acuity, OCT and the NEI VFQ-
25 will be assessed at baseline, after 6 and 12 months,
the questionnaires at baseline and after 12 months. An
independent research assistant of the university will
enter the data directly into the SPSS program (version
18.0 or higher).
Monitoring
At least two outreach visits will be performed in each
centre, the first briefly after study onset and the second
during the study year. The aim of these outreach visits
are to assess if the ETDRS assessments will be con-
ducted in a standardized way according the predefined
specifications (adherence of correct distance of 4 m, use
of standardized ETDRS charts etc.). Furthermore these
visits aim to support the CCC and to reveal possible
problems which might have occurred and to discuss and
implement appropriate solutions. The outreach visits
will be performed by a study coordinator.
Sample size
The primary endpoint is the visual acuity. To asses
visual acuity, we will perform a standardized ETDRS
test. According to previous data, we assumed a mean of
48 and a standard deviation (SD) of 15 letters for the
patients with AMD [33,34]. We hypothesized that a
change of 5 letters can be achieved (of 70 letters in
total, 5 per row, 14 rows), which can be regarded as
clinically relevant. According to these assumptions, a
number of 282 patients is needed to achieve a power of
80% and a significance level of 5%. Assuming a drop out
rate of 25% the total sample size has to be 352. This
number of patients would also be sufficient to detect a
difference of 5 points in the NEI VFQ-25. According to
the Manual of the National Eye Institute for the VFQ-
25, version 2000 [21], Table eight (Sample sizes needed
per group to detect differences in change over time
between two experimental groups for the VFQ-25,
repeated measures design), 161 patients in each treat-
ment arm are needed to detect a minimum change in
the VFQ-25 of 5 points, which has been defined as clini-
cally relevant [35,36].
Recruitment of centres
Around 20 specialised medical doctors (MDs) from 20
leading centres in Switzerland which provide therapy
with anti-angiogenic drugs for AMD patients will be
invited by a formal letter of the Institute of General
Practice and Health Services Research of the University
of Zurich to an information meeting. The content of the
meeting is to provide the MDs with detailed information
about the study, the specific intervention and the asso-
ciated efforts for participation. If a centre agrees to par-
ticipate in the study, it will be provided with all the
required information and material and it will have to
d e s i g n a t eaC C Cw h ow i l lb et r a i n e di nao n ed a y
session.
Randomization
Eligible patients will be informed about the study by
their physicians in the centres. After giving their
informed consent, patients will be enrolled consecutively
by the CCC in the study and allocated randomly in a
1:1 ratio to the intervention or control group (usual
care, no intervention) (block randomization, stratified by
study centre). A randomization list will be computed by
means of STATA statistical software program version
11 and provided step by step for each patient to the
centres/chronic care coach by telephone by the Institute
of General Practice. We aim the physician to be blind
regarding to the allocation.
Statistical methods
To determine whether the intervention is associated
with a change in the visual acuity score, we perform a
2-sided t-test to compare the mean ETDRS values in
the intervention and the control group. Further analyses
Frei et al. Trials 2011, 12:221
http://www.trialsjournal.com/content/12/1/221
Page 6 of 8include the regression of ETDRS depending on a set of
variables including treatment group, age, gender, disease
duration and years of education, taking multiple obser-
vations over time into account.
The primary data analysis will follow the intention-to-
treat (ITT) principle which means that the data will be
analyzed according to the original treatment group
assignment regardless of whether or not each individual
actually received the assigned treatment. Corresponding
to an intention-to-treat-analysis the data of drop out
patients will be integrated into the follow up analyses.
For missing values we will assume the mean of the
value in the control group. A last observation carried
forward approach (LOCF) is inappropriate, because the
outcome would be overestimated as we investigate
patients with a chronic degenerative ocular disease. We
will also compare if there are any differences in the
characteristics between the drop-out and the patients
remaining in the study.
Description of risks
Serious risks or undesired effects of the CCM or the
assessment by questionnaires have not been described in
the literature. There are no specific risks related to the
study.
Ethical principles
The study is being conducted in accordance with medi-
cal professional codex and the Helsinki Declaration as
of 1996 as well as Data Security Laws and according to
the Guidelines of Good Clinical Practice.
Study participation of patients is voluntary and can be
cancelled at any time without provision of reasons and
without negative consequences for their future medical
care.
Patient informed consent
Previous to study participation patients receive written
and spoken information about the content and extent of
the planned study; for instance about potential benefits
for their health and potential risks. In case of acceptance
they sign the informed consent form.
Vote of the ethics committee
The study protocol has been approved by the ethics
board of the Kanton Zurich on 17.12.2010 (KEK-ZH-
NR: 2010-04391/1).
Data security/disclosure of original documents
The patient names and all other confidential information
fall under medical confidentiality rules and are treated
according to the appropriate Federal Data Security Law.
All study related data and documents are stored on a
protected central server of the University of Zurich.
Only direct members of the internal study team can
access the respective files.
Intermediate and final reports are stored in the office
of the Institute of General Practice and Health Services
Research at the Zurich University Hospital.
Discussion
The CCM has achieved widespread acceptance as an
evidence based template for the care of chronically ills.
Wet AMD has the same characteristics as the diseases
for which the CCM has been established as e.g. diabetes:
Its natural course leads to a continuous loss in visual
acuity. On the other hand there are established treat-
ments available. The effectiveness of these treatments
largely depends on a frequent application. Similar to
diabetes, where a frequent follow-up and a proactive
approach with action before the disease gets worse is
effective, wet AMD has to be treated before visual acuity
gets worse or completely lost. Therefore the characteris-
tics of wet AMD qualify it as a “classic” chronic disease.
Thus it can be assumed that some of the elements of
the CCM, mainly the frequent follow up by a structured
case management, will result in better clinical outcomes.
Multiple studies have shown that implementing CCM
elements improve clinical outcomes as well as process
parameters in different chronic diseases as osteoarthritis,
depression or e.g. the cardiovascular risk profile of dia-
betes patients. This study will for the first time assess this
approach in wet AMD. If our hypothesis will be con-
firmed, the implementation of this approach in routine
care for patients with wet AMD should be considered.
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